These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 2866786

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bucindolol, a beta-adrenoceptor blocker with vasodilatory action: its effect in systemic hypertension.
    Rotmensch HH, Rocci ML, Vlasses PH, Swanson BN, Fedder IL, Soyka L, Ferguson RK.
    Am J Cardiol; 1984 Aug 01; 54(3):353-6. PubMed ID: 6147080
    [Abstract] [Full Text] [Related]

  • 3. Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.
    Müller FB, Allsopp LF, Cooper GL, Bolli P, Frei P, Glaus L, Ritz R, Bühler FR.
    Br J Clin Pharmacol; 1985 Aug 01; 19 Suppl 2(Suppl 2):207S-212S. PubMed ID: 4005124
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Short- and long-term studies of bucindolol in mild to moderate hypertension: efficacy, safety, and exercise responses.
    Rosendorff C, Goodman C, Coull A.
    J Clin Pharmacol; 1985 Apr 01; 25(3):233-6. PubMed ID: 2860134
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Concentration-effect relationships for oxprenolol in patients with essential hypertension.
    McInnes GT, Brodie MJ.
    Br J Clin Pharmacol; 1988 May 01; 25(5):539-45. PubMed ID: 3408634
    [Abstract] [Full Text] [Related]

  • 12. Double-blind comparison of metoprolol, alprenolol, and oxprenolol in hypertension.
    Tuomilehto J, Nissinen A.
    Eur J Clin Pharmacol; 1979 May 01; 16(6):369-74. PubMed ID: 393518
    [Abstract] [Full Text] [Related]

  • 13. Bucindolol in essential hypertension.
    Reid JL, Curzio J, Vincent J.
    Int J Clin Pharmacol Res; 1985 May 01; 5(5):293-301. PubMed ID: 2866166
    [Abstract] [Full Text] [Related]

  • 14. A comparison of the effects of the slow release formulations of metoprolol and oxprenolol in hypertension.
    Comerford MB, Besterman EM.
    Ann Clin Res; 1982 Feb 01; 14(1):27-31. PubMed ID: 7137874
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative beta-adrenoceptor blocking effect and pharmacokinetics of bucindolol and propranolol in man.
    Maury M, Berdeaux A, Kher A, Duhaze P, Giudicelli JF.
    Eur J Clin Pharmacol; 1985 Feb 01; 27(6):649-56. PubMed ID: 2859199
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.
    McInnes GT, Brodie MJ.
    Eur J Clin Pharmacol; 1988 Feb 01; 34(6):605-11. PubMed ID: 3169112
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antihypertensive and hemodynamic effects of oxprenolol versus propranolol.
    Ferlinz J, Easthope JL, Hughes D, Siegel J, Tobis J, Aronow WS.
    Clin Pharmacol Ther; 1980 Jun 01; 27(6):733-43. PubMed ID: 6991196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.